Abstract: A number of studies have reported that patients with schizophrenia have a higher body mass index (BMI) than the general population. Few Asian studies have examined BMI in patients with schizophrenia. The aims of the current study were to evaluate the distribution of BMI and prevalence of obesity in a large sample of Chinese patients with schizophrenia (n = 973) and to examine the sociodemographic and clinical correlates of overweight (BMI Q25 kg/m 2 ) and obesity (BMI Q30 kg/m 2 ). There was a preponderance of patients who were overweight (58.7%) and obese (73.6%) as compared with control subjects. Regression modeling of clinical and symptom factors in schizophrenia patients revealed that females were almost twice as likely to be obese compared with males and patients with comorbid medical conditions were more likely to be obese compared with those who did not have a comorbid medical condition (odds ratio, 1.6). Those prescribed typical antipsychotic medications were 1.7 times more likely to be obese, whereas individuals prescribed with both typical and atypical antipsychotic medications were 2.2 times more likely to be obese as compared with those prescribed atypical antipsychotics. A significant predictor interaction for obesity was observed between sex and typical antipsychotics, sex and comorbid medical conditions, and years of education and comorbid medical conditions. The higher prevalence of obesity in patients with schizophrenia is a matter of clinical and public health concern; interventions to reduce weight to healthy levels would result in both improved health and quality of life among patients with schizophrenia.
A number of studies have reported that patients with schizophrenia have a higher body mass index (BMI) than the general population. 1Y3 There are very few Asian studies on BMI in patients with schizophrenia. While a study from Taiwan reported a higher prevalence of obesity and severe obesity among patients as compared with the Taiwanese reference population, 4 Kitabayashi et al 5 reported that among Japanese inpatients with schizophrenia, the mean BMI was within reference range and much lower as compared with that from Western studies. They also found a higher frequency of both obese and underweight patients and a lower frequency of individuals with normal weight in their patient population. Factors contributing to the higher prevalence of obesity and higher BMI include the use of antipsychotic medications, 6Y8 poor dietary habits, and lack of physical exercise in patients with schizophrenia. 9Y11 Sex is believed to play a role in weight gain and obesity among patients with schizophrenia, with some studies reporting higher BMIs and obesity rate among female patients, 12 whereas others found that both male and female patients had similar prevalence. 13 Obesity in patients with schizophrenia has been found to be associated with many adverse outcomes such as cardiovascular diseases, 14, 15 higher mortality, 14 reduced quality of life, 16 and poor compliance. 17 However, some studies have suggested that in the acute phase of treatment, beneficial outcomes are associated with weight gain in both male and female patients with schizophrenia. 18, 19 In a sample of 722 long-term schizophrenia patients, Salokangas et al 13 found that in male patients low BMI was associated with poor functioning as assessed by the Global Assessment Scale.
Singapore is an island city-state nation in Southeast Asia. In 2009, the population was just under 5 million, of which 3.7 million were Singapore residents. Of its residents, 74.2% are of Chinese descent, 13.4% are Malays, and 9.2% are of Indian descent. As with most developed countries, obesity is a growing problem in Singapore, with a recent health survey showing that the prevalence of obesity was 10.8% in 2010 among adults aged 18 to 69 years. 20 In 2008, a research program was established at the Institute of Mental Health in Singapore to study the biomarkers of schizophrenia. 21, 22 Institute of Mental Health is the only tertiary care provider of mental health services in Singapore; it has an inpatient population of about 2000 and annual outpatient attendances of about 150,000. The aims of the current study, which is part of the research program, were (i) to evaluate the distribution of BMI and prevalence of obesity in a large sample of Chinese patients with schizophrenia and (ii) to examine the sociodemographic and clinical correlates of overweight and obesity.
METHODS

Participants
Patients were mainly recruited from the outpatient clinics of the Institute of Mental Health following referrals from their psychiatrists. Control subjects were recruited from the community using various methods such as snowballing technique, newspaper advertisements, e-mail blasts, and so on. All patients met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis for schizophrenia as ascertained by clinical evaluations conducted via the Structured Only respondents with no history of DSM-IV psychotic disorder (as assessed by SCID) and without any history of schizophrenia spectrum disorders in first-degree relatives were included as control subjects. All participants were of Chinese ethnicity, and those with neurological conditions and current substance abuse or dependence were excluded. The study was approved by the relevant institutional and ethics committees. Before data collection, study procedures were explained to all research subjects, and only those who gave written informed consent were included in the study. Sociodemographic data including age, sex, years of education, and smoking status were collected from all participants. Additional data on age at onset of illness, duration of illness, comorbid medical conditions, and current medication history were also collected using semistructured questionnaires. The daily dose of neuroleptic drugs was recorded and converted into chlorpromazine (CPZ) equivalent.
24,25
Clinical Measurements
Trained psychologists assessed all patients and control subjects using SCID for DSM-IV Axis I disorders. Regular meetings were held with clinicians to resolve doubts or conflicting information. Psychopathology and symptom severity in patients were assessed using the Positive and Negative Syndrome Scale (PANSS). 26 Training and interreliability exercises were conducted by PANSS training institute personnel, and only certified psychologists and clinicians were allowed to do the PANSS assessments.
Height and Weight Measurements
The body weight and height of all subjects were measured in standardized settings to calculate the BMI (weight in kilograms divided by height 2 in meters squared). Weight and height were measured using an electronic machine (Body Mass Index System Model B100 Aramech; Avalanche Mechtronics, Singapore) equipped with a load cell for weight measurement and an ultrasonic sensor for height measurement. This machine is widely used by public institutions including hospitals and schools in Singapore. The weight and height were measured in kilograms and meters, respectively, and the data were generated on the screen attached to the machine. Subjects were asked to stand upright and barefoot on the platform while taking their measurements. The weight categories based on BMI followed the World Health Organization criteria, and to facilitate international comparisons, standard cutoffs were used. The cutoff points were as follows: underweight, less than 18 
RESULTS
Nine hundred seventy-three patients with schizophrenia participated in the study consisting of 525 men (54.0%) and 448 women (46%); their mean age was 41.7 T 11.0 years, and their age at diagnosis was 24.1 T 7.6 years. The total PANSS mean score was 49.6 (SD, 13.6) in the patient sample, whereas the mean PANNS positive, negative, and general psychopathology scores were 12.2 (SD, 5.0), 12.7 (SD, 5.3), and 24.9 (SD, 6.9), respectively. The sample of nonpsychiatric participants, that is, control subjects, comprised 1012 individuals; their mean age was 36.1 T 10.8 years with a sex distribution of 529 men (52.3%) and 483 women (47.7%). The 2 groups, that is, patients and control subjects, differed significantly in their age at the time of interview, years of education, and smoking status, with patients being significantly older, having lesser years of education, and more likely to be current smokers. The sociodemographic characteristics of the sample are described further in Table 1 .
Case-Control Comparisons
There was a preponderance of patients who were overweight (BMI, 25Y29.9 kg/m 2 ) (58.7%) and obese (BMI, Q30 kg/m 2 ) 
Sex Comparisons
Case-control comparisons were repeated after stratifying the sample by sex. Results indicated that female schizophrenia patients tend to be more overweight or obese compared with male schizophrenia patients (Fig. 1 ). There were also greater case-control discrepancies in females for normal and underweight BMI ranges compared with males, pointing to a potential upward BMI shift in female schizophrenia patients.
Associations With Obesity and Being Overweight
Among control subjects, sex, age, smoking status, and years of education were modeled as predictors for obesity and being overweight as independent outcome variables. Standardized residuals that represent individual probabilities for being obese were saved for subsequent comparisons. In patients, hierarchical logistic regression was conducted to allow for 3 blocks of predictors: (i) demographic factors (sex, age, smoking status, and years of education), (ii) clinical factors (daily antipsychotic dose in CPZ equivalents, duration of psychiatric illness, comorbid medical conditions), and (iii) symptom factors (PANSS positive, PANSS negative, and PANSS general psychopathology).
Demographic Modeling
In control subjects, only age accounted for increased likelihood of obesity. However, association effects for age and obesity in control subjects were small. Age, sex, and smoking status were significant factors for being overweight in control subjects, where being a smoker increased the odds of being overweight and females were less likely to be overweight as compared with males (Table 2) .
Association patterns of demographic factors with obesity and being overweight were different in patients. Sex was significantly associated with obesity, with females more likely to be obese than males. Years of education exhibited small but significant protective effects for obesity and being overweight in schizophrenia. Age was associated with being overweight but not with obesity.
Clinical and Symptom Factors in Schizophrenia
Logistic regression modeling of clinical and symptom factors in schizophrenia revealed that females were almost twice as likely to be obese compared with males, and patients who were diagnosed with comorbid medical conditions were more likely to be obese compared with those who did not have a comorbid medical condition (odds ratio [OR], 1.6). With patients who were prescribed atypical antipsychotic medications as the reference group, those prescribed typical antipsychotic medications were 1.7 times more likely to be obese, whereas individuals prescribed with both typical and atypical antipsychotic medications were 2.2 times more likely to be obese (Table 3) .
We did not identify any predictors that showed significant association with being overweight in schizophrenia. Clinical symptoms (PANSS score) were not significant in predicting either obesity or being overweight in the logistic regression analysis.
First-order interaction effects for each significant predictor of obesity were entered as a separate predictor block to examine potential moderating and mediating effects between significant predictors of obesity (Table 3) . A forward likelihood ratio criterion was chosen to filter first-order interactions that were not significant to keep the model parsimonious. Significant predictor interaction was found between sex and typical antipsychotics, sex, and comorbid medical conditions, as well as years of education and comorbid medical conditions.
BMI Adjustment in Cases and Control Subjects
We examined if predictors found to be significant in the initial analysis were sufficient in explaining BMI differences between schizophrenia patients and control subjects. Standardized BMI scores were entered in a logistic regression model with cases and control subjects as dependent. A significant effect of BMI was observed; schizophrenia patients were more likely to have higher BMI compared with control subjects (OR, 1.7; 95% confidence interval [CI], 1.5Y1.8). However, when adjusted for sex, years of education, smoking status, comorbid medical conditions, and types of antipsychotic medication, although there was still a significant difference between patients and control subjects, between-group effect sizes were reduced by approximately half (OR, 1.3; 95% CI, 1.2Y1.4). No significant differences were observed between cases and control subjects once age and sex effects were adjusted in control subjects as well.
BMI and Clinical Symptoms
The PANSS, positive, negative, and general psychopathology composites were examined to ascertain if there were any differences by BMI categories in schizophrenia patients. BMI status was binary coded 1 and 0 for individuals being underweight, normal weight, overweight, and obese compared against other patients. Underweight-normal weight, underweight-overweight and underweight-obese, normal-overweight and normal-obese pairings were tested using nonparametric Mann-Whitney U test. We found that individuals who were underweight scored higher on the PANSS general psychopathology scale compared with individuals with normal weight (% mean rank difference = 9.5, Z = j2.253, P = 0.024). Underweight individuals also scored higher on general psychopathology compared with overweight individuals (% mean rank difference = 9.4, Z = j2.140, P = 0.032). No other differences were observed between weight statuses.
To understand if a unique symptom profile might be associated with weight status of the patients, nonparametric Mann-Whitney U test was also conducted using individual PANSS items as outcome variables and BMI status as a predictor. Results revealed significant differences on suspiciousness, depression, uncooperativeness, volitional disturbances, and active social avoidance scales (Fig. 2) . Results indicated that schizophrenia patients who were underweight were more likely to have higher scores on selected PANSS indicators (Table 4) .
DISCUSSION
Results from our study showed a significant difference between the BMIs of the patients as compared with control subjects. The mean BMI among our patients was 25.1 T 5.3 kg/m 2 , which is just above the cutoff for overweight as suggested by World Health Organization. The prevalence of obesity in our sample was 15.6%, which was significantly higher than that of 5.1% in our control subjects and among those of Chinese ethnicity in the general population of Singapore of 7.9%. While our study replicates the findings of a number of other studies that have established that BMI levels are higher in individuals with schizophrenia as compared with those without the illness, 2Y4 the rate of obesity among individuals with schizophrenia in our sample was much lower than that reported by other studies. Hsiao et al 4 reported that severe obesity in their study as defined by a cutoff of 28.6 kg/m 2 , was found in 23.3% of male patients and 27.9% of female patients. Coodin 1 reported obesity in their sample of patients to be 42.1%, whereas Gurpegui et al 28 reported that 24% of those with schizophrenia were obese in their study sample. There are a number of possible causes for this observed difference between our study and these other studies pertaining to differences in the study samples such as age, sex, ethnicity, diet, lifestyle, and differential exposure to antipsychotic medications.
It is well established that patients with schizophrenia have poor dietary habits; they tend to be smokers and are often overweight or obese. McCreadie 9 established that patients with schizophrenia had a predicted increased risk over the next 10 years of both coronary heart disease and stroke. Population studies have established that increased BMI is associated with increased prevalence of diabetes mellitus, hypertension, and dyslipidaemia. 29 Thus, the association of obesity and medical 30 reported that the prevalence of obesity in women was higher among those with less than a bachelor's degree, compared with more educated women, but they did not find any association between obesity and education among men. While we did not find this association in our control subjects, we did find a similar association in our patients with schizophrenia; that is, those with lower education had a higher risk of obesity. Lower education may be associated with obesity via complex causal pathways; possible explanations include the fact that a high level of education could mean a greater degree of awareness and knowledge pertaining to the health issues of weight and weight control. A higher education could also mean high socioeconomic status with greater access to healthier food and access to maintain a healthier lifestyle including the means to exercise. 31 Whereas among control subjects, a BMI of 25 kg/m 2 or greater was associated with males, among patients, a BMI of 30 kg/m 2 or greater was found to be associated with female sex. Our findings of an association of female sex with obesity among patients with schizophrenia are consistent with other studies. 3, 28, 32 The sex-related differences identified in our study and others are likely to be multifactorial. It has been suggested that these differences may be caused by differences in pharmacokinetics between male and female patients. A rather unique finding of our study is that we found that females on typical antipsychotics were more likely to be obese compared with males on typical antipsychotic medication. Tamminga et al 33 found sex differences in the activity of CYP450 enzymes, which in turn could lead to differences in plasma concentrations and therapeutic and metabolic profiles of antipsychotics such as olanzapine and clozapine. 34 It is thus possible that there are genetically determined sex differences in response to drug therapy. A study by Zhang et al 35 found that brain-derived neurotrophic factor levels in female patients with schizophrenia negatively correlated with weight gain. They suggested that brain-derived neurotrophic factor may be an additional adiposity signal in female patients with schizophrenia treated with antipsychotics.
We did not find any association with daily CPZ equivalent dose among those who were either overweight (includes obesity) or obese. Salokangas et al 13 similarly reported that daily doses and type of antipsychotics were not associated with BMI and suggested that the acute and short-term effects of neuroleptics may be different from their long-term effects.
We found that patients who were underweight scored higher on the PANSS general psychopathology scale compared with normal weight and overweight patients. Those who were underweight scored significantly higher on items related to suspiciousness, depression, uncooperativeness, volitional disturbances, and active social avoidance. Considerable research has been done to identify an association between antipsychotic response and weight gain. Clozapine has been studied extensively, and findings suggest that weight gain is associated with greater improvement in psychopathology. 19, 36, 37 Similarly, a positive association between clinical response and weight gain has been shown in those taking olanzapine. 38 Yang et al 39 found that patients who had the greatest weight gains while receiving olanzapine, risperidone, clozapine, or quetiapine showed greater improvements in symptoms than those showing lower weight gain in their study population of Han Chinese patients with schizophrenia. Interestingly, they also found that significant BMI increases in patients during atypical antipsychotic treatment were associated with a j604 G/A polymorphism in the ghrelin gene. Girgis et al 40 have suggested a unique model to explain the association between therapeutic effects and metabolic adverse effects of antipsychotic medications. They have suggested that the ability of an antipsychotic drug to enhance signaling via the insulin signaling pathway rather than traditional D 2 receptor mechanisms leads to greater efficacy. They hypothesize that medications that are more prone to affect this pathway such as clozapine and olanzapine are also more likely to be associated with metabolic adverse effects. We speculate that either the insulin signaling pathway and/or other pathways that have both an antipsychotic and metabolic effect may explain our findings.
To our knowledge, this is one of the largest studies that has assessed BMI among Chinese patients with schizophrenia. The strengths of our study include the fact that it was a single-site study where all measurements of weight and height were done using the same instrument and techniques. We also established a unique association between BMI and PANSS scores in patients with schizophrenia. The limitations of our study are that we did not include other measures of obesity such as waist-hip ratio, total body fat composition, or lipid levels. We also did not examine the diet or exercise patterns among the 2 groups. The patients were recruited from a clinical setting, and this might limit the generalizability of our findings to those in the general population. The study design was cross-sectional, and patients would have changed their antipsychotic medication during the course of their illness; thus, it is difficult to draw conclusions about obesity and type of antipsychotic medication. Lastly, we did not include other measures of functioning such as global assessment of functioning as studies have shown a strong relationship between the global assessment of functioning and BMI. 41 The higher prevalence of obesity in patients with schizophrenia is a matter of clinical and public health concern. Obese individuals have a higher risk of hyperlipidemias, cardiovascular diseases, and certain types of cancers, 42 and the higher mortality rates in schizophrenia patients as compared with the general population are well established. 43, 44 Although obesity alone is not responsible for the increased morbidity and mortality among patients with schizophrenia, interventions to reduce weight to healthy levels would result in both improved health and quality of life among patients with schizophrenia. 45 
